Form 4: Moderna CLO Shannon Klinger Executes Stock Transactions

Moderna Chief Legal Officer Shannon Klinger reported the vesting and partial sale of restricted stock units to cover tax obligations.

Summary

• Chief Legal Officer Shannon Klinger acquired 773 shares of common stock on May 27, 2026, through the vesting of restricted stock units (RSUs).
• On the same day, 374 shares were withheld at a price of $47.03 to satisfy tax obligations.
• On May 28, 2026, Klinger acquired an additional 328 shares through RSU vesting.
• On May 28, 2026, 159 shares were withheld at a price of $47.61 to satisfy tax obligations.
• Following these transactions, Klinger holds 66,350 shares of Moderna common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding executive equity compensation.

Positives

• The transactions reflect the standard vesting of equity compensation, indicating ongoing alignment between executive interests and shareholder value.

Negatives

• None identified; these are routine administrative transactions related to tax withholding.

Risks

• None identified; this is a standard disclosure of executive equity activity.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that routine RSU vesting and tax-related share withholding are standard practices for executive compensation in the biotechnology sector and do not typically signal changes in corporate strategy or outlook.

Comparison to Industry Standards

• The transaction structure is consistent with standard executive compensation practices at large-cap pharmaceutical companies like Pfizer, Merck, and Amgen.

Stakeholder Impact

• Minimal impact on shareholders as these transactions are part of pre-existing compensation plans.

Next Steps

• None indicated.

Key Dates

Keywords

Moderna, MRNA, Insider Trading, Form 4, Equity Compensation, Shannon Klinger